MiMedx® is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. To date, over 40 clinical and scientific papers have been published in peer-reviewed journals on our amniotic tissue-based technologies. The Company’s extensive product portfolio is covered by over 45 issued patents, with more than 90 patents pending. Our PURION®, PURION® Plus, and LyoPur™ Processed allografts are clinically effective, and more than 1,000,000 allografts have been distributed.
For more information, visit: www.mimedx.com